Perspectives
How does this study impact clinical practice?
- The use of preventative medications in patients can be stopped with realistic and informed expectations for continued good functioning.
- The data informs use and stopping of newer therapies in pediatric/youth patient populations.
- Adds to the ongoing active debate about use of preventative medications in youth, as although the FDA approved topiramate for the treatment of episodic migraine in adolescents 12 to 17 years of age during the CHAMP trial, it did not perform better in the trial, which had a high placebo rate.1
- This provides the long-term follow-up data necessary for 2019 practice guidelines.2